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Despite advances in diagnostic imaging, antimicrobial treatment 
and cardiac surgery, infective endocarditis (IE), as defined by the 
modified Duke criteria,[1] remains a potentially fatal condition with 
an annual in-hospital mortality rate of ~20%.[2,3] Observational 
data from the developed world indicate that the profile of IE has 
changed significantly over the past four decades. IE has become a 
disease that predominantly affects older and/or diabetic patients 
with infections on degenerative native valves or prosthetic valves. 
Rheumatic heart disease (RHD) has all but disappeared as a 
predisposing risk factor. [4-6] The classic clinical signs of IE are 
now infrequent, patients often presenting with only fever and/
or a heart murmur. [4] Furthermore, endocarditis caused by oral 
organisms (such as Streptococcus viridans) and culture-negative 
endocarditis have both declined significantly as a proportion of 
IE in the developed world.[4] Nosocomial infections from long-
term indwelling catheters and intravenous lines are increasing in 
incidence, and Staphylococcus aureus, coagulase-negative S. aureus 
and Enterococcus spp. are the dominant organisms. [7] In spite of 
this evolution in the patient and clinical profile of IE, in-hospital 
mortality, morbidity and complication rates remain high. Specifically, 
congestive cardiac failure, stroke and intracardiac abscesses with 
conduction abnormalities are reported at frequencies of ~60%, 30% 
and 1 - 15%, respectively.[8–11]
Apart from a recent focus on intravenous (IV) drug use (IVDU)-
related IE,[12] there are few contemporary data on IE from South 
Africa (SA) or sub-Saharan Africa (SSA), with the most recent 
information on the subject published in 2003.[13] Specifically, 
there is a dearth of information on patient profiles, risk factors, 
predisposing cardiac conditions, and the spectrum of causative 
microbiological organisms. Furthermore, little is known about 
the prevalence and predictors of complications, the proportion of 
patients with IE who undergo surgery, and in-hospital mortality 
rates in SSA. This knowledge is vital for increasing the survival of IE 
patients as well as improving their overall care by optimising local 
clinical practice.
Objectives
This study was conducted to address these gaps in our local 
knowledge, providing a contemporary and descriptive overview of IE 
in a representative SA tertiary centre.
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Background. Little is known about the current clinical profile and outcomes of patients with infective endocarditis (IE) in South Africa (SA).
Objectives. To provide a contemporary and descriptive overview of IE in a representative SA tertiary centre.
Methods. We conducted a retrospective review of the records of patients admitted to Groote Schuur Hospital, Cape Town, between 2009 
and 2016 fulfilling universal criteria for definite or possible IE, in search of demographic, clinical, microbiological, echocardiographic, 
treatment and outcome information.
Results. A total of 105 patients fulfilled the modified Duke criteria for IE. The median age of the cohort was 39 years (interquartile 
range (IQR) 29 - 51), with a male preponderance (61.9%). The majority of the patients (72.4%) had left-sided native valve endocarditis, 
14.3% had right-sided disease, and 13.3% had prosthetic valve endocarditis. A third of the cohort had rheumatic heart disease. Although 
41.1% of patients with left-sided disease had negative blood cultures, the three most common organisms cultured in this subgroup were 
Staphylococcus aureus (18.9%), Streptococcus spp. (16.7%) and Enterococcus spp. (6.7%). Participants with right-sided endocarditis were 
younger (29 years, IQR 27 - 37) and were mainly intravenous drug users (73.3%), and the majority cultured positive for S. aureus (73.3%) 
with frequent septic pulmonary complications (40.0%). The overall in-hospital mortality was 16.2%, with no deaths in the group with right-
sided endocarditis. Predictors of death in our patients were heart failure (odds ratio (OR) 8.16, 95% confidence interval (CI) 1.77 - 37.70; 
p=0.007) and age >45 years (OR 4.73, 95% CI 1.11 - 20.14; p=0.036). Valve surgery was associated with a reduction in mortality (OR 0.09, 
95% CI 0.02 - 0.43; p=0.001).
Conclusions. IE remains an important clinical problem in a typical teaching tertiary care centre in SA. In this setting, it continues to affect 
mainly young people with post-inflammatory valve disease and congenital heart disease. The in-hospital mortality associated with IE 
remains high. Intravenous drug-associated endocarditis caused by S. aureus is an important IE subset, comprising ~10% of all cases, which 
was not reported 15 years ago, and culture-negative endocarditis remains highly prevalent. Heart failure in IE carries a significant risk of 
death and needs a more intensive level of care in hospital. Finally, cardiac surgery was associated with reduced mortality, with the largest 
impact in patients with heart failure.
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Methods
This was a retrospective review of 
patient records. Patients aged >17 years 
with complete data who fulfilled the 
modified Duke criteria for IE[14] and were 
commenced on treatment for possible or 
definite IE at Groote Schuur Hospital in 
Cape Town in 2009 - 2016 were included. 
After approval by the University of Cape 
Town’s Human Research Ethics Committee 
(ref. no. 517/2016), 181 potential cases 
were identified by screening the hospital’s 
electronic database for all hospital 
admis sions and referrals to cardiology. 
Demographic, clinical, microbiological, 
echocardiographic, laboratory and outcome 
data were collected on all identified cases.
Six independent investigators (MCdV, 
CAV, CvdW, AS, MR and MG) used a 
standardised data collection form, from 
which data were entered into REDCap 
(Research Electronic Data Capture, a 
secure online database manager hosted 
at the University of Cape Town). All the 
collected data were verified. Collected data 
were exported from the REDCap database 
to Stata  software, version 14.1 (StataCorp, 
USA), for statistical analysis. Descriptive 
statistics were used to summarise demo-
graphic, clinical and microbiological varia-
bles. Univariable and multivariable logistic 
regression analysis was used to determine 
the association between clinically relevant 
variables and inpatient mortality in patients 
with left-sided IE. Variables were selected 
a  priori and were excluded if data were 
sparse. Those considered for regression 
analysis were age, sex, comorbidities 
(including HIV status), serum creatinine, 
white cell count, organism cultured, 
echocardiographic complications, clinical 
complications and valve replacement surgery 
performed. Variables were retained in the 
multivariable model if the p-value was <0.25 
or if an association had been demonstrated 
in previous studies.[15,16] Unadjusted and 
adjusted odds ratios (ORs) were presented 
with 95% confidence intervals (CIs).
Results
One hundred and five cases were included 
in the study (Fig. 1), with 64.8% (n=68) 
and 35.8% (n=37) of patients fulfilling the 
modified Duke criteria for definite and 
possible IE, respectively. In all cases, the 
responsible clinicians felt it appropriate to 
commence treatment for endocarditis. There 
was a steady increase in the number of cases 
seen over the period from 2009 to 2016, 
with a peak in 2014 (Supplementary File 1, 
available at http://www.samj.org.za/public/
sup/Supplementary.pdf).
The median age of the cohort was 39 years 
(interquartile range (IQR) 29 - 51), with 
a slight male preponderance (61.9%). The 
majority of the patients had left-sided 
native valve endocarditis (72.4%), while 
the remainder were evenly split between 
prosthetic valve endocarditis (13.3%) and 
right-sided endocarditis (14.3%).
The most common underlying cardiac 
conditions were RHD (34.3%), mechanical 
or tissue prosthetic valves (13.3%; most of 
these patients had had valve surgery for 
RHD), and congenital heart disease (10.5%). 
Five patients (4.8%) had a prior history 
of IE and 1 patient had device-associated 
endocarditis (permanent pacemaker). 
Among those who were tested for HIV 
(87/105 patients), 23.0% were seropositive. 
Ten patients (9.5%) had diabetes mellitus, 
while other comorbidities such as chronic 
kidney disease, chronic liver disease and 
cancer were uncommon (3 patients each). 
One patient had a permanent IV port. 
Table 1 gives a detailed description of the 
clinical characteristics, special investigations 
and laboratory results. The most frequent 
presenting signs and symptoms were fever 
(63.8%), dyspnoea (61.0%), a temperature 
>38.5°C (58.1%) and weight loss (24.8%). 
Most patients (85.7%) had a new or changed 
murmur on clinical examination. More than 
a quarter (27.6%) had an acute neurological 
deficit, and 18.1% were noted to have splinter 
haemorrhages (Table 2).
All patients had a transthoracic echo-
cardiogram. Where vegetations were detec-
ted, the mitral valve (52.9%) and aortic 
valve (37.6%) were most frequently affected. 
Two-thirds (68.4%) of the patients with 
aortic valve involvement had severe aortic 
regurgitation, whereas 54.1% of those with 
mitral involvement and 36.4% of those 
with tricuspid involvement had severe 
regurgitation.
The median number of blood cultures 
done per patient was 3 (IQR 2.5 - 4.5). Blood 
cultures were persistently positive after 
48  hours in 21.0% of patients in this study 
(13.2% of left-sided native endocarditis, 
42.9% of prosthetic valve endocarditis and 
40.0% of right-sided endocarditis; p=0.006). 
Based on the attending clinician’s evalua tion, 
the most frequent sources of infection were 
thought to be the skin (66.7%), oral cavity 
(25.9%) and gastrointestinal tract (7.9%). 
Of patients with left-sided disease, 40.7% 
had negative blood cultures (Fig. 2, A), and 
the three most common organisms cultured 
in this subgroup were S. aureus (18.7%), 
Streptococcus spp. (16.5% (S. viridans 9.9%, 
other 6.6%)) and Enterococcus spp. (6.6%).
Right-sided disease differed from left-
sided disease. Patients with tricuspid and 
pulmonary valve endocarditis were younger 
than those with left-sided disease (median 
age 29.1 years, IQR 27 - 37) and had a 
greater male predominance (73.3%), IVDU 
was a common risk behaviour (73.3%) and 
Potential cases
N=181
Denite IE
n=68
Possible IE
n=37
Did not meet criteria
n=47
Folders missing
n=18
Incomplete notes
n=11
Rejected
n=76
Included
n=105
Fig. 1. Patients included in the study. (IE = infective endocarditis.)
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S. aureus was the most common organism cultured (73.3%), while 
13.3% of patients were culture-negative (Fig. 2, B).
In-hospital course and outcome
Heart failure was the most common in-hospital complication (42.9%) 
(Table 3), followed by embolic complications (36.1%), acute kidney 
injury (21.9%) and pneumonia (8.6%). In-hospital mortality was 
observed only in patients with left-sided native and prosthetic 
valve endocarditis, with a rate of 18.9% in that subgroup. Heart 
failure (adjusted OR 8.16, 95% CI 1.77 - 37.70; p=0.007) and age 
>45 years (adjusted OR 4.73, 95% CI 1.11 - 20.14; p=0.036) were 
significantly associated with an increased in-hospital mortality in 
this study (Table 4); however, data sparsity reduced the precision of 
these estimates. HIV, diabetes and infection with S. aureus did not 
appear to influence mortality. The most common complications for 
right-sided disease were septic pulmonary emboli (40.0%) and acute 
kidney injury (40.0%).
All patients were treated with antibiotics, and 44 (42.3%) underwent 
valve surgery. Heart failure was the most common indication for 
surgery (66.7%; p=0.001). Surgery was associated with a reduced risk 
Table 1. Demographics, comorbidities, clinical characteristics and mortality of patients with left- and right-sided IE
Total (N=105) Left-sided disease (N=90) Right-sided disease (N=15)
Sex male, n (%) 65 (61.9) 54 (60.0) 11 (73.3)
Age (years), median (IQR) 39 (29 - 51) 42.7 (31 - 53) 29.1 (27 - 37)
Congenital heart disease, n (%) 11 (10.5) 9 (10.0) 2 (13.3)
RHD, n (%) 36 (34.3) 36 (40.0) 0
Previous IE, n (%) 5 (4.8) 5 (5.6) 0
Prosthetic valves, n (%) 14 (13.3) 14 (15.6) 0
No comorbidities, n (%) 31 (29.5) 20 (22.2) 11 (73.3)
HIV, n (%) 20/87 (23.0) 20/75 (26.6) 0/12
IVDU, n (%) 15 (14.2) 4 (4.5) 11 (73.3)
Diabetes mellitus, n (%) 10 (9.5) 9 (10.0) 1 (6.7)
Ethanol use, n (%) 23 (21.9) 23 (21.9) 0
Native valve IE, n (%) 91 (86.7) 76 (84.4) 15 (100)
Prosthetic valve IE, n (%) 14 (13.3) 14 (15.6) 0
Duke criteria definite, n (%) 68 (64.8) 53 (58.9) 15 (100)
Echocardiography
LVEF, % (IQR) 60 (53 - 66) 59.5 (53 - 65) 64 (58 - 70.5)
Vegetations present, n (%) 85 (81.0) 71 (78.9) 14 (93.3)
Aortic regurgitation, n (%) 39 (37.1) 38 (42.2) 1 (6.7)
Mitral regurgitation, n (%) 62 (59.1) 60 (66.7) 2 (13.3)
Pulmonary regurgitation, n (%) 9 (8.6) 8 (8.9) 1 (6.7)
Tricuspid regurgitation, n (%) 34 (32.4) 23 (21.9) 11 (73.3)
Laboratory values
WCC (× 109/L), median (IQR) 12.7 (8.3 - 15.7) 11.5 (7.7 - 15.4) 14.95 (13.8 - 18.5)
Hb (g/dL), median (IQR) 10.1 (8.5 - 11.4) 10.3 (8.8 - 11.4) 9.15 (7 - 11.6)
Creatinine (µmol/L), median (IQR) 89.5 (67 - 120) 87 (67 - 110) 121.5 (62 - 209)
Diuretic use, n (%) 62/100 (59.1) 58/86 (64.5) 4/14 (28.6)
Valvular surgery performed, n (%) 44 (42.3) 43 (47.8) 1 (6.7)
Inpatient mortality, n (%) 17 (16.2) 17 (18.9) 0
IE = infective endocarditis; IQR = interquartile range; RHD = rheumatic heart disease; IVDU = intravenous drug use; LVEF = left ventricular ejection fraction; WCC = white cell count;  
Hb = haemoglobin concentration.
Table 2. Presenting signs and symptoms of patients with left- and right-sided IE
Total (N=105), n (%) Left-sided disease (N=90), n (%) Right-sided disease (N=15), n (%)
Fever 67 (63.8) 54 (60.0) 13 (86.7)
Dyspnoea 64 (61.0) 57 (61.5) 7 (46.7)
Poor appetite 13 (12.4) 12 (13.3) 1 (6.7)
Weight loss 26 (24.8) 22 (24.4) 4 (26.7)
Neurological deficit 29 (27.6) 28 (31.1) 1 (6.7)
Arthralgia 11 (10.5) 8 (8.9) 3 (20.0)
Temperature >38.5oC 61 (58.1) 51 (56.7) 10 (66.7)
Clubbing 32 (30.5) 28 (31.1) 4 (26.7)
New or changed murmur 90 (85.7) 79 (87.8) 11 (73.3)
Splinter haemorrhages 19 (18.1) 17 (18.9) 2 (13.3)
Haematuria on urine test strip 44/64 (68.8)* 35/54 (64.8) 9/10 (90.0)
IE = infective endocarditis.
*Data missing on 41 patients.
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of death (OR 0.09, 95% CI 0.02 - 0.43; p=0.001). Only one patient 
with right-sided endocarditis underwent surgery, i.e. tricuspid valve 
repair due to severe tricuspid regurgitation.
Discussion
We have presented a retrospective review of the hospital records 
of patients admitted to an SA urban tertiary referral centre with a 
diagnosis of IE. The study, which covered the period between 2009 
and 2016, is the first of its kind since the early 2000s and describes 
the demographic, clinical and microbiological profile of patients 
with the disease, discusses treatment strategies, and provides 
information about in-hospital outcomes and their predictors.
The main findings of this study demonstrate that IE in urban 
SA remains a disease of relatively young people (median age 
39 years) with rheumatic or congenital heart disease (44.8%); 
culture-negative endocarditis remains a prevalent problem; the 
proportion of IE caused by community-acquired S. aureus appears 
to be growing; and there is evidence that IVDU-associated right-
sided endocarditis is now an important problem. Furthermore, 
we found that heart failure was the most common complication of 
IE, was the most important predictor of death and was the main 
reason patients were referred for cardiac surgery, an intervention 
that was associated with reduced mortality rates. Finally, HIV, 
diabetes, alcohol use and chronic kidney disease were not important 
predictors of a poor outcome.
Although no major conclusions can be made from a retrospective 
review, or from comparisons with other studies, it is interesting 
to compare our findings with data from recent international 
registries[4,17-20] and a similar but older SA study.[13] When compared 
with our findings, these registries suggest that there are major 
differences in the age profile (>70 years v. <40 years), clinical profile 
(degenerative valve disease v. RHD) and microbiological profile 
of the studied IE patients, with apparently fewer cases of culture-
negative and oral organism-related IE seen in the developed world.
Additionally, in comparison with findings from the earlier 
SA study,[13] the main observed differences revolved around the 
microbiological profile, proportion of IVDU-associated right-sided 
disease, and prevalence of underlying congenital heart disease.
Whereas community-associated S. aureus was noted infrequently 
in 2003, it was found in 26% of our overall cohort and was the 
dominant cause of infection in patients with IVDU-associated IE. 
This is in line with a recently published study from Johannesburg, 
which found S. aureus to be present in 61% of recreational drug users 
who developed IE.[12] The same study reported a higher burden of 
right-sided endocarditis at their centre compared with our findings. 
This finding could possibly be explained by recent data on drug abuse 
in SA that showed higher rates of IVDU in Gauteng Province than in 
the Western Cape.[21] On the other hand, viridans group streptococci, 
which were previously dominant, may be diminishing in frequency. 
The high rate of culture-negative IE in our cohort was in line with the 
previous study and other low- and middle-income country (LMIC) 
data, as demonstrated in a systematic review by Njuguna et al.[22] High 
rates of empirical administration of antibiotics prior to blood culture 
collection are often cited as the main reason for high culture-negative 
IE rates. Of patients with culture-negative IE in our study, 24.8% 
had received antibiotics prior to blood culture collection. Culture-
Viridans 
streptococci 
13.3%
No organism 
13.3%
Staphylococcus 
aureus 73.3%
No organism 
40.7%
Staphylococcus 
aureus 18.7%
Viridans 
streptococci 9.9%
Enterococci 
6.6%
HACEK group 
3.3%
Coagulase-negative 
staphylococci 
6.6%
Other 
streptococci 
6.6%
Coxiella 
burnetii 
2.2%
Other 
5.5%
A B
Fig. 2. Microbiological profile of (A) left-sided and (B) right-sided IE. (IE = infective endocarditis; HACEK = Haemophilus spp., Aggregatibacter spp., 
Cardiobacterium hominis, Eikenella corrodens and Kingella spp., a group of fastidious Gram-negative bacteria that are an unusual cause of IE.)
Table 3. Complications in patients with IE (N=105)
n (%)
Heart failure 45 (42.9)
Embolic 38 (36.1)
Ischaemic stroke 15 (14.3)
Mycotic aneurysm 8 (7.6)
Septic pulmonary emboli 6 (5.7)
Pulmonary infarct 2 (1.9)
Splenic infarct 2 (1.9)
Cerebral abscess 2 (1.9)
Intracranial haemorrhage 3 (2.9)
Acute kidney injury 23 (21.9)
Pneumonia 9 (8.6)
Septic shock 7 (6.7)
IE = infective endocarditis.
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negative rates are significantly lower in higher-income countries 
(10%).[4]
Mortality in our cohort (16.2%) was lower than figures previously 
reported in other LMICs (19 - 46%).[22] A possible explanation for 
this relatively lower than expected mortality was the liberal use 
of cardiac surgery for patients with international guideline-based 
recommendations such as heart failure.[23] Approximately 48% of 
patients with left-sided IE underwent surgery, a much higher figure 
than those reported in other LMIC registries, where ~15% receive 
valve replacement for the same indication.[22,24]
Study strengths and limitations
To the best of our knowledge, this is the largest cohort of IE patients 
in SSA to date and provides important information and insight 
into the disease in an SA context. There are a number of important 
limitations of this study, including that it was a single-centre, 
retrospective study; that the number of participants was relatively 
small; that the subgroup sizes were relatively small and unequal; 
that it is likely that not all patients with IE over the given period of 
interest were captured; and that some patient records may have been 
incomplete and their International Statistical Classification of Diseases 
and Related Health Problems, 9th revision (ICD-9) and ICD-10 
information may not always have been accurate. As a result of these 
and other limitations inherent in the design and conduct of such a 
study, caution needs to be exercised with regard to the conclusions 
drawn as well as the generalisability of the findings.
Conclusions
IE in a typical teaching tertiary care centre in SA remains an important 
clinical problem. In this setting, it continues to affect mainly young 
people with post-inflammatory valve disease and congenital disease 
and is associated with in-hospital mortality that is quite high at almost 
20%. Intravenous drug-associated endocarditis caused by S.  aureus 
is an important IE subset, comprising ~10% of all cases, which was 
not reported 15 years ago, and culture-negative endocarditis remains 
highly prevalent. Heart failure in IE carries a significant risk of death 
and needs a more intensive level of care in hospital. Finally, cardiac 
surgery reduced mortality and had most impact in patients with 
heart failure. These findings suggest that prospective cohorts of IE 
are needed to keep track of changing trends and profiles in order 
to provide clinicians with more robust information to inform their 
clinical practice and thereby improve patient outcomes.
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Table 4. Univariable and multivariable logistic regression analysis of clinically relevant risk factors associated with inpatient 
mortality in patients with left-sided endocarditis*
Univariable regression analysis, 
unadjusted OR (95% CI) p-value
Multivariable regression analysis, 
adjusted OR (95% CI) p-value
Age >45 years 3.73 (1.26 - 11.09) 0.018 4.73 (1.11 - 20.14) 0.036
Diabetes mellitus 2.39 (0.53 - 10.73) 0.225 0.85 (0.12 - 6.15) 0.870
Staphylococcus aureus 1.42 (0.40 - 5.06) 0.589 2.04 (0.41 - 10.23) 0.386
Heart failure 1.83 (0.63 - 5.34) 0.269 8.16 (1.77 - 37.70) 0.007
Valvular surgery performed 0.18 (0.05 - 0.67) 0.011 0.09 (0.02 - 0.43) 0.001
OR = odds ratio; CI = confidence interval; IE = infective endocarditis.
*Analysis was restricted to patients with left-sided IE, as risk profiles differ between right- and left-sided IE. There were insufficient data to conduct a similar analysis in the right-sided cohort.
